Skip to main
LENZ
LENZ logo

LENZ Stock Forecast & Price Target

LENZ Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LENZ Therapeutics has successfully completed a comprehensive clinical program, including three Phase 3 trials under its CLARITY program, demonstrating strong efficacy and safety that position it favorably within the market. The company is expected to experience continued growth in baseline annual spending levels, potentially expanding beyond FY27, which indicates increasing demand for its therapeutic offerings. Furthermore, financial forecasts project that LENZ will achieve profitability by 2028, bolstered by plans to enhance its sales force in response to positive trial outcomes.

Bears say

LENZ Therapeutics faces significant commercial challenges in changing consumer behavior regarding the treatment of presbyopia, which could limit market acceptance of its product, Vizz. Additionally, the company's lack of a diversified pipeline beyond Vizz raises concerns about long-term growth potential and reliance on a single product for revenue generation. Moreover, competitive dynamics and the risk of generic challenges to Vizz's intellectual property may further hinder the company's market position and financial prospects.

LENZ has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LENZ Therapeutics Inc (LENZ) Forecast

Analysts have given LENZ a Buy based on their latest research and market trends.

According to 4 analysts, LENZ has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LENZ Therapeutics Inc (LENZ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.